Abbisko Therapeutics is a Shanghai-based therapeutics company. The company has closed a $42-million Series B funding round. The article states the round was led by Qiming Venture Partners. No other investors are named in the article. The article does not provide details on Abbisko's products, pipeline, revenue, users, or future plans. The piece also does not disclose the intended use of proceeds or any operating metrics. Abbisko Therapeutics develops immuno-oncology drugs with a focus on small-molecule therapies targeting cancers with high incidence in Asian populations, including lung, liver, stomach and esophageal cancers. Its core pipeline comprises three preclinical compounds led by ABSK001, which is in lead optimization. The company also maintains early-stage programs in liver disease, viral infections and central nervous system disorders. Abbisko plans to use new financing to set up R&D teams and discovery centers and to advance its anticancer programs into clinical trials. The startup was set up last year and is located in the Zhangjiang biotech cluster in Shanghai. It is led by founder and CEO Yao-Chang Xu, a 25-year industry veteran with prior roles at Hansoh BioMedical, Novartis Institutes for BioMedical Research and Eli Lilly.

Total raised

$70M

Funding rounds

2

Latest round

Series B

Latest activity

Mar 2019